+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Generics in Singapore

  • PDF Icon

    Report

  • 35 Pages
  • December 2024
  • Region: Singapore
  • MarketLine
  • ID: 6052901
Generics in Singapore industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

  • A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
  • The Singaporean generics market recorded revenues of $0.5 billion in 2023, representing a compound annual growth rate (CAGR) of 3.6% between 2018 and 2023.
  • Market consumption volume increased with a CAGR of 0.1% between 2018 and 2023, to reach a total of 90.0% of total pharma volume in 2023.
  • According to the publisher, in 2023, the Singaporean generics market grew by 4.9% annually. The growth is attributed to the country’s mounting aging population, with a high prevalence of chronic diseases such as hypertension, diabetes, and cardiovascular conditions. According to the United States Census Bureau, in 2023, the population aged 65 years and above in Singapore reached 810.5 thousand, up 10.0% over 2022.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Singapore
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Singapore
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Singapore generics market with five year forecasts

Reasons to Buy

  • What was the size of the Singapore generics market by value in 2023?
  • What will be the size of the Singapore generics market in 2028?
  • What factors are affecting the strength of competition in the Singapore generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Singapore's generics market?

Table of Contents

1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Have there been any recent developments in the market?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Ltd
8.2. Novartis International AG
8.3. Beacons Pharmaceuticals Pte Ltd
8.4. Abbott Laboratories SA
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related research
10.4. About the Publisher
List of Tables
Table 1: Singapore generics market value: $ million, 2018-23
Table 2: Singapore generics market volume: % of total pharma volume, 2018-23
Table 3: Singapore generics market geography segmentation: $ million, 2023
Table 4: Singapore generics market value forecast: $ million, 2023-28
Table 5: Singapore generics market volume forecast: % of total pharma volume, 2023-28
Table 6: Teva Pharmaceutical Industries Ltd: Key Facts
Table 7: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Ltd: Key Employees
Table 9: Novartis International AG: Key Facts
Table 10: Beacons Pharmaceuticals Pte Ltd: Key Facts
Table 11: Abbott Laboratories SA: Key Facts
Table 12: Singapore Size of Population (million), 2019-23
Table 13: Singapore Real GDP (Constant 2010 Prices, $ Billion), 2019-23
Table 14: Singapore GDP (Current Prices, $ Billion), 2019-23
Table 15: Singapore Inflation, 2019-23
Table 16: Singapore Consumer Price Index (Absolute), 2019-23
Table 17: Singapore Exchange Rate, 2018-23
List of Figures
Figure 1: Singapore generics market value: $ million, 2018-23
Figure 2: Singapore generics market volume: % of total pharma volume, 2018-23
Figure 3: Singapore generics market geography segmentation: % share, by value, 2023
Figure 4: Singapore generics market value forecast: $ million, 2023-28
Figure 5: Singapore generics market volume forecast: % of total pharma volume, 2023-28
Figure 6: Forces driving competition in the generics market in Singapore, 2023
Figure 7: Drivers of buyer power in the generics market in Singapore, 2023
Figure 8: Drivers of supplier power in the generics market in Singapore, 2023
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Singapore, 2023
Figure 10: Factors influencing the threat of substitutes in the generics market in Singapore, 2023
Figure 11: Drivers of degree of rivalry in the generics market in Singapore, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Teva Pharmaceutical Industries Ltd
  • Novartis International AG
  • Beacons Pharmaceuticals Pte Ltd
  • Abbott Laboratories SA